Haemonetics (HAE) Azione Prezzo
Haemonetics Prezzo
Negli ultimi 19 anni Haemonetics ha aumentato il fatturato del 5,9% all'anno, raggiungendo 1,33 miliardi USD. L'utile per azione è cresciuto del 4,5% all'anno negli ultimi 19 anni. Per Haemonetics, il margine netto del 7,3% risulta in aumento rispetto al 4,4% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Haemonetics è 96,00 USD, circa il 5,6% sotto il prezzo attuale di mercato. Su 15 analisti, 11 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Haemonetics Prezzo delle azioni
Haemonetics Azione e analisi azionaria
Domande frequenti sull'azione Haemonetics
The business model of Haemonetics Corp focuses on providing innovative and comprehensive solutions for blood and plasma collection, as well as transfusion medicine. This global healthcare company specializes in the development and manufacturing of devices and software that aid in blood management, including blood processing systems, information technology solutions, and donor management software. Haemonetics Corp aims to improve patient outcomes and enhance operational efficiency in blood and plasma centers, hospitals, and other healthcare settings worldwide through its integrated offerings.
Haemonetics Corp is primarily active in the healthcare industry.
Haemonetics Corp has several key competitors in the market. Some of its main competitors include Fresenius Kabi AG, B. Braun Melsungen AG, and Terumo Corporation. These companies also operate in the healthcare industry, specifically in the blood management and hematology sectors. However, Haemonetics Corp distinguishes itself through its innovative medical devices and advanced solutions, making it a formidable competitor in the market.
Haemonetics Corp is a renowned global healthcare company specializing in blood management solutions. Founded in 1971, Haemonetics has been actively shaping the medical industry for over five decades. The company's core focus lies in providing innovative devices, software, and services to enhance blood and plasma collection, processing, and transfusion. Haemonetics serves a wide range of healthcare providers, including blood banks, hospitals, and plasma fractionators. With its commitment to advancing patient care and blood safety, Haemonetics has become a trusted partner for healthcare institutions worldwide. Through continuous research and development, the company remains at the forefront of the industry, constantly expanding its product portfolio and improving blood management practices.
Haemonetics Corp has achieved several significant milestones throughout its history. One notable achievement is the development and introduction of the industry's first fully automated blood processing system, called PCS2. This innovative system has revolutionized the way blood components are collected, processed, and stored. Another important milestone for Haemonetics Corp is the acquisition of Pall Corporation's blood transfusion and filtration business in 2012, which expanded their product portfolio and global presence. Furthermore, the company has continuously focused on research and development to enhance its offerings, resulting in numerous product advancements and patents. Haemonetics Corp's commitment to innovation has solidified its position as a leading provider of blood management solutions.
Haemonetics Corp is primarily present in various countries and regions around the world. The company has a global presence and operates in several key markets including the United States, Europe, Asia-Pacific, and Latin America. It serves healthcare providers and blood banks in these regions, offering innovative blood management solutions for improved patient outcomes. Haemonetics Corp's commitment to expanding its operations internationally has allowed it to establish a strong foothold in the global healthcare industry.
Haemonetics Corp represents values of innovation, quality, and efficiency in the healthcare industry. The company is dedicated to providing advanced blood management solutions that improve patient outcomes and enhance safety. Haemonetics Corp embraces a corporate philosophy centered around collaboration, customer focus, and continuous improvement. Their commitment to delivering cutting-edge technologies and services is reflected in their strong market position and global presence. With a focus on advancing the standard of care, Haemonetics Corp strives to make a positive impact on the lives of patients and healthcare providers alike.
Gli analisti fissano attualmente un prezzo obiettivo medio di 95,40 USD per l’azione Haemonetics (mediana: 96,00 USD), pari a -6,2 % rispetto all’ultimo prezzo. Il consenso si basa su 15 giudizi di analisti.
15 analisti valutano attualmente l’azione Haemonetics: 11 raccomandano l’acquisto, 4 la tenuta e 0 la vendita.
Convertita al tasso di cambio attuale, l’azione Haemonetics quota 90,82 EUR (101,71 USD).
L’azione Haemonetics (HAE) è quotata su 3 borse, tra cui: NYSE (HAE), Frankfurt (HAZ.F), München (HAZ.MU).
Haemonetics Corp is a leading global provider of innovative blood processing systems and medical devices for the healthcare and biotechnology industries. The company offers a wide range of products divided into three main business segments: Plasma, Blood, and Hospital. The Plasma division of Haemonetics Corp focuses on the development and manufacturing of systems for the collection, processing, and storage of plasma for use in life-saving therapies. These systems are specifically designed for blood donation services, plasma collection centers, and pharmaceutical manufacturers. The company has developed a number of innovative plasma separation systems such as PCS2 and PCS2 plus, which utilize the benefits of microprocessors to automate the processing process while reducing processing time. The Blood division of the company offers a range of devices and systems for blood processing, such as the Cell Saver System for blood transfusion during surgical procedures and the OrthoPAT Advance System for the collection and processing of autologous blood for use in orthopedic procedures. The company has also developed a variety of devices to support blood transfusions, such as the TEG Systems, which provides real-time information on blood clotting. Haemonetics Corp also focuses on developing innovative solutions for hospital departments and clinical facilities. The company offers solutions for blood and plasma collection in clinical facilities and hospitals, such as the TEG 5000 Thrombelastograph Hemostasis Analyzer System or the Cell Saver Elite System, which can be used directly during surgery. The company also provides solutions for patient data management and documentation, such as eAuto Blood Bank or SafeTrace Tx blood management software, to ensure better patient care and safety. Haemonetics Corp promotes the success of its business models through a strong market presence and effective management of distribution channels. Investments in research and development have contributed to the creation of innovative products and services that provide a competitive advantage. Overall, Haemonetics Corp is a leading provider of blood processing systems and medical devices that contribute to making the healthcare industry safer and more effective. The company has the ability to adapt to rapidly changing needs while maintaining a strong leadership position in the industry.
Il fatturato di Haemonetics ammonta a 1,33 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il profitto di Haemonetics ammonta a 97,31 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Haemonetics è attualmente 47,77. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Haemonetics.
Il rapporto prezzo/fatturato (P/S) di Haemonetics è attualmente 3,48. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Haemonetics.
Il Quality Score AlleAktien per Haemonetics è 3/10.
L'ISIN di Haemonetics è US4050241003. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Haemonetics è 881782. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Haemonetics è HAE. Con questo simbolo di borsa vengono negoziate le azioni Haemonetics in borsa.
Azione Haemonetics
Gruppo di pari di Haemonetics
Haemonetics Ticker
Haemonetics FIGI
Altre metriche e analisi di Haemonetics in Deep Dive.
La nostra analisi azionaria dell'azione Haemonetics include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Haemonetics. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: